Qvar with a dose counter (beclomethasone dipropionate HFA; Teva) is now commercially available in the United States. Qvar with a dose counter was approved in May 2014 by the Food and Drug Administration (FDA) following their guidance recommending that metered-dose inhalers (MDI) should have a clear indication of when it is approaching the end of its recommended number of actuations.

Qvar is indicated for the maintenance treatment of asthma as prophylactic therapy in patients ≥5 years of age. It is also indicated for asthma patients who require systemic corticosteroid administration, where adding Qvar may reduce or eliminate the need for the systemic corticosteroids.

RELATED: FDA Approves Qvar With Dose Counter

Beclomethasone dipropionate is a corticosteroid demonstrating potent anti-inflammatory activity. Corticosteroids have been shown to have multiple anti-inflammatory effects, inhibiting both inflammatory cells (eg, mast cells, eosinophils, basophils, lymphocytes, macrophages, and neutrophils) and release of inflammatory mediators (eg, histamine, eicosanoids, leukotrienes, and cytokines).

Qvar is available in 40mcg and 80mcg strengths containing 120 actuations.

For more information call (888) 838-2872 or visit Qvar.com.